Rohit R. Arora, MD, FACC, FAHA, FACP, FSCAI
Professor of Medicine
Professor of Physiology and Biophysics
Chairman of Cardiology
Associate Chairman of Medicine for Research
The Chicago Medical School
H. Edward Davidson, PharmD, MPH
Assistant Professor, Clinical Internal Medicine
Eastern Virginia Medical School
Partner, Insight Therapeutics, LLC
Pharmacists: 1.25 Contact Hours (0.125 CEUs)
NOTE: This activity was presented on November 10, 2010, in conjunction with ASCP's Annual Meeting and Exhibition.
Participants who received credit for attending either the live presentation or the webcast on that date are not eligible to receive credit for this online activity.
Approximately 2.2 million people in the United States have been diagnosed with atrial fibrillation (AF), the most common cardiac arrhythmia, and the risk of stroke in these patients is substantial. In older adults, AF leads to 25% of all strokes. Because of the rapid and serious consequences of stroke, effective preventive treatment is of utmost importance to reduce disability and improve survival in elderly patients with AF. Many older adults with AF who are at high risk of stroke continue to experience unnecessary risk for stroke due to inaccurate risk assessment and suboptimal anticoagulation therapy.
Senior care pharmacists play an important role on the clinical team in ensuring that older adults with AF benefit from optimal anticoagulation to prevent stroke. This activity will provide information to improve knowledge about risk assessment for stroke and anticoagulant strategies for older adults with AF to tailor treatments to maximize efficacy and minimize adverse events.
This educational activity is designed to meet the needs of consultant and senior care pharmacists.
Upon completion of this knowledge-based educational activity, the participant should be able to:
Outline ways to improve the risk assessment process and documentation for older adults with atrial fibrillation who reside in long-term care settings.
Define the optimal anticoagulant strategy for an older adult with atrial fibrillation based on available therapies.
Identify ways to tailor treatment approaches to maximize anticoagulation efficacy and minimize adverse effects.
Evaluate the potential role of emerging anticoagulant agents for the prevention of stroke in patients with atrial fibrillation.
In accordance with the standards set forth by the Accreditation Council for Pharmacy Education, it is the policy of the American Society of Consultant Pharmacists to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker¹s interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Arora has no relevant financial relationships with any commercial interests to disclose.
Dr. Davidson discloses that he has served on the speakers' bureau for sanofi-aventis.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity, UAN 203-999-10-109-H01-P, has been assigned 1.25 Contact Hours (0.125 CEUs).
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit. Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test.
Partial credit cannot be awarded.
There is no fee to participate in this educational activity.
Commercial Support Statements
Supported through an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Minimum System Requirements:
• Pentium III, 600 MHz or Equivalent Processor
• 512 MB of RAM
• Windows XP, Vista, or 7. Or, Mac OS X
• 800x600 Monitor Resolution
• 16-bit Color
• 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The activity will take approximately 60 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. A credit statement/certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.